Related Experiment Videos
Recent studies in novel therapy for metastatic sarcomas
Dejka M Steinert1, Shreyaskumar R Patel
1Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Unit 10, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hematology/Oncology Clinics of North America
|June 9, 2005
Summary
New chemotherapy drugs and targeted therapies show promise for metastatic soft tissue sarcomas (STSs). This review covers recent clinical studies on agents like gemcitabine and imatinib mesylate for STS treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic soft tissue sarcomas (STSs) present significant treatment challenges.
- The development of novel chemotherapeutic and targeted agents is crucial for improving patient outcomes.
Purpose of the Study:
- To review recent clinical study results for various chemotherapeutic agents and targeted therapies in metastatic STSs.
- To summarize the activity of specific drugs including gemcitabine, docetaxel, paclitaxel, ecteinascidin, 9-nitrocamptothecin, pegylated liposomal doxorubicin, imatinib mesylate, SU11248, everolimus, and bortezomib.
Main Methods:
- Review of recent clinical studies and trial data.
- Synthesis of published research on therapeutic agents for STSs.
Main Results:
- Gemcitabine, docetaxel, paclitaxel, ecteinascidin, 9-nitrocamptothecin, and pegylated liposomal doxorubicin have been evaluated in clinical studies for STS.
- Targeted therapies including imatinib mesylate, SU11248, everolimus, and bortezomib demonstrate activity in STSs.
Conclusions:
- The landscape of STS treatment is rapidly evolving with new chemotherapeutic and targeted therapy options.
- Ongoing research continues to identify effective strategies for managing metastatic soft tissue sarcomas.